Rituximab vs Cyclophosphamide Induction Therapy for Patients With Granulomatosis With Polyangiitis.

ABSTRACT:

Importance

Results of randomized clinical trials have demonstrated rituximab's noninferiority to cyclophosphamide as induction therapy for antineutrophil cytoplasm antibody (ANCA)-associated vasculitides (AAV), with neither treatment having a specific advantage for granulomatosis with polyangiitis (GPA). However, post hoc analysis results have suggested that rituximab might be more effective than cyclophosphamide in inducing remission in patients with proteinase 3-positive AAV.

Objective

To compare the effectiveness of rituximab and cyclophosphamide in inducing GPA remission in a large population of unselected patients.

Design, setting, and participants

This comparative effectiveness study used multicenter target trial emulation observational data from 32 French hospi

SUBMITTER: Puechal X 

PROVIDER: S-EPMC9706346 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature